...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: major disconnect in Share price/value to other biotech is same space

We have discussed many many times the major issue with current share valuation with RVX as big problem that management has either not dealed with appropriately or are having issues solving it.

My big issue is what has Russo & partners been hired to do, ?? They are not geting the message out to the right people, ie new investors, institutional investors, new brokerage analysts news media outlets etc

If RVX had some either major news or media in a major publication such as bloomberg or Forbes on the huge science possibilty breakthrough going into a phase 3 trial I think we would get a major pop. For us long investors I can remember a few years back (if my memory is right was in 2010 in forbes magazine on RVx, The share price spiked very quickly from $2 to $8 right after or somewhere in that range This was during phase 2 trials.

The potential is huge if the message was sent at the right time to the right people, institutional investors, analysts. IMO we should be at a higher evaluations than that of our peers ESPR yet we are at 10% of there market cap. THis is a major disconnect that managment need to solve right away

Share
New Message
Please login to post a reply